The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 23ANDME HOLDING CO | CLASS A COM | 90138Q108 | 9,357,092 | 10,243,122 | SH | SOLE | 10,243,122 | 0 | 0 | |||
| ALECTOR INC | COM | 014442107 | 10,436,707 | 1,307,858 | SH | SOLE | 1,307,858 | 0 | 0 | |||
| FOGHORN THERAPEUTICS INC | COM | 344174107 | 10,150,758 | 1,573,761 | SH | SOLE | 1,573,761 | 0 | 0 | |||
| ISHARES TR | MSCI INDIA ETF | 46429B598 | 118,371,279 | 2,425,144 | SH | SOLE | 2,425,144 | 0 | 0 | |||
| NGM BIOPHARMACEUTICALS INC | COM | 62921N105 | 852,272 | 992,168 | SH | SOLE | 992,168 | 0 | 0 | |||
| ORIC PHARMACEUTICALS INC | COM | 68622P109 | 9,102,572 | 989,410 | SH | SOLE | 989,410 | 0 | 0 | |||
| PMV PHARMACEUTICALS INC | COM | 69353Y103 | 8,145,693 | 2,627,643 | SH | SOLE | 2,627,643 | 0 | 0 | |||
| RAPT THERAPEUTICS INC | COM | 75382E109 | 16,348,790 | 657,899 | SH | SOLE | 657,899 | 0 | 0 | |||
| SPDR GOLD TR | GOLD SHS | 78463V107 | 265,726,300 | 1,390,000 | SH | SOLE | 1,390,000 | 0 | 0 | |||
| SPDR S&P 500 ETF TR | TR UNIT | 78462F103 | 435,926,289 | 917,141 | SH | SOLE | 917,141 | 0 | 0 | |||
| SURROZEN INC | COM NEW | 86889P208 | 824,342 | 87,696 | SH | SOLE | 87,696 | 0 | 0 | |||
| SURROZEN INC | *W EXP 08/01/203 | 86889P117 | 3,314 | 170,833 | SH | SOLE | 170,833 | 0 | 0 | |||
| TENAYA THERAPEUTICS INC | COM | 87990A106 | 3,290,884 | 1,015,705 | SH | SOLE | 1,015,705 | 0 | 0 | |||